Title
External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents
Date Issued
01 January 2011
Access level
open access
Resource Type
journal article
Author(s)
Vardas E.
Giuliano A.R.
Goldstone S.
Palefsky J.M.
Moreira E.D.
Aranda C.
Jessen H.
Moi H.
Ferris D.G.
Liaw K.L.
Marshall J.B.
Vuocolo S.
Barr E.
Haupt R.M.
Garner E.I.O.
Guris D.
Abstract
Background. We examined the baseline prevalence of penile, scrotal, and perineal/perianal human papillomavirus (HPV) in heterosexual men (HM). We also evaluated baseline characteristics of HM to assess factors associated with prevalent HPV detection. Methods. We tested serum samples from 3463 HM aged 16-24 years with 1-5 lifetime female sexual partners for antibodies to HPV 6, 11, 16, and 18. We collected baseline swab specimens for the detection of DNA of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 from 3 areas: penile, scrotal, and perineal/perianal. Risk factors for prevalent HPV DNA detection were evaluated. Results. The prevalence of any tested HPV type was 18.7% at the penis, 13.1% at the scrotum, 7.9% at the perineal/perianal region, and 21.0% at any site. Having >3 lifetime female sexual partners had the greatest impact on HPV prevalence: odds ratio (OR) 3.2 (95% confidence interval (CI) 2.1-4.9) for HPV 6, 11, 16, and 18; and OR 4.5 (95% CI 3.3-6.1) for all HPV types tested. HPV DNA detection was highest in Africa. Neither condom usage nor circumcision was associated with HPV DNA prevalence. Conclusion. Genital-HPV DNA detection is common in young, sexually active HM. We found HPV to be most prevalent in African men and least prevalent in men from the Asia-Pacific region. Increased numbers of sexual partners was an important risk factor for HPV DNA prevalence. © The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.
Start page
58
End page
65
Volume
203
Issue
1
Language
English
OCDE Knowledge area
Virología Temas sociales
Scopus EID
2-s2.0-79851472653
PubMed ID
Source
Journal of Infectious Diseases
ISSN of the container
00221899
Sponsor(s)
Potential conflicts of interest: DGF, EM, MP, AG, and JP have received research grants from Merck, either personally or through their institutions. MP and DGF have received research grants from GlaxoSmithKline. AG, SG, DGF, RJH, and EM have received honoraria from Merck for speaking engagements or board membership. SG, AG, DGF, JP and EM have received travel reimbursement from Merck related to scientific meetings. CA has an approved, filed, or pending patent related to subject matter discussed in this manuscript. EG, EB, RMH, DG, JBM, KLL and SV are employees of Merck and may own Merck stock and/or stock options.
Sources of information: Directorio de Producción Científica Scopus